ArticleInfectious diseases and therapy2026
Immunogenicity and Safety of Single-Dose MenACYW Conjugate Vaccine in Vietnamese Participants Aged ≥ 12 Months: A Phase III, Open-Label Study.
Article in Infectious diseases and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06228586 (A Phase III, Open-label, Single-center Study to Describe the Immunogenicity and Safety of a Single Dose of MenACYW Conjugate Vaccine in Participants Aged 12 Months and Older in Vietnam), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Phase III, Open-label, Single-center Study to Describe the Immunogenicity and Safety of a Single Dose of MenACYW Conjugate Vaccine in Participants Aged 12 Months and Older in Vietnam
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionInvasive meningococcal disease (IMD) is a progressive condition commonly presenting as septicemia and meningitis, with significant mortality and morbidity. Vietnam reports high incidence rates among military populations and young infants. Despite this burden and unpredictable outbreaks, meningococcal vaccination in Vietnam is offered primarily to high-risk individuals and travelers rather than as routine childhood immunization. MenACYW-TT, a quadrivalent meningococcal polysaccharide tetanus toxoid-conjugate vaccine with licensure in > 80 countries, is approved for toddlers aged ≥ 12 months and for infants aged ≥ 6 weeks. This Phase III, open-label study evaluated the immunogenicity and safety of a single dose of MenACYW-TT in healthy Vietnamese participants aged ≥ 12 months.
methodsThis study (NCT06228586) was conducted in Vietnam among healthy participants aged ≥ 12 months (five age groups) who received a single dose of MenACYW-TT. Functional antibody activity against all four meningococcal serogroups was measured using serum bactericidal assay with human complement (hSBA) at baseline (Day 1) and after vaccination (Day 31). Safety data were collected up to 30 days (+ 14 days) after vaccination.
resultsAmong the 447 enrolled participants, seroprotection rates (hSBA titers ≥ 1:8) were high and comparable across all age groups for each serogroup, i.e., 88.8% for serogroup A to 100% for serogroup C. Overall, the seroresponse rates were high for serogroups C: 98.6%, Y: 96.0%, W: 95.0%, and A: 73.6%, with higher seroresponse to serogroup A in the 12- to 23-month group (81.5%) versus the ≥ 24-month group (66.5%). No safety concerns or vaccine-related serious adverse events were observed.
conclusionsA single dose of MenACYW-TT induced robust immunogenicity against all four serogroups and demonstrated an acceptable safety profile across all age groups of Vietnamese participants. Given the high burden of meningococcal disease in Vietnam, these findings support the potential inclusion of MenACYW-TT in Vietnam's National Expanded Program on Immunization.
trial registrationclinicaltrials.gov, NCT06228586.
Indexed as
Identifiers
42862517What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.